Distribution pattern of lymph node metastases and its implication in individualized radiotherapeutic clinical target volume delineation of regional lymph nodes in patients with stage IA to IIA cervical cancer

Radiation Oncology

Volumn 10, Issue 1, 2015, Pages

  Li, Xinglan ^a,b   Yin, Yueju ^a   Sheng, Xuigui ^a   Han, Xiaoyun ^a   Sun, Li ^a   Lu, Chunhua ^a   Wang, Xiang ^a,b  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Cervical cancer; Pelvic lymphadenectomy; Radiotherapy; Target volume

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OBTURATOR; PELVIS LYMPHADENECTOMY; PERSONALIZED MEDICINE; RADICAL HYSTERECTOMY; UTERINE CERVIX CANCER; ADENOCARCINOMA; CANCER GRADING; CARCINOMA, SQUAMOUS CELL; FOLLOW UP; LYMPH NODE; MIDDLE AGED; PATHOLOGY; PELVIC NEOPLASMS; PROCEDURES; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING SYSTEM; RETROSPECTIVE STUDY; SECONDARY; TUMOR INVASION; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PELVIC NEOPLASMS; PRECISION MEDICINE; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84924273228     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/s13014-015-0352-5     Document Type: Article

References (36)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Okazawa M, Mabuchi S, Isohashi F, Suzuki O, Ohta Y, Fujita M, et al. The prognostic significance of multiple pelvic node metastases in cervical cancer patients treated with radical hysterectomy plus adjuvant chemoradiotherapy. Int J Gynecol Cancer. 2012;22:490-7.
3. Sakuragi N. Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer. Int J Clin Oncol. 2007;12:165-75.
4. Taylor A, Powell ME. Conformal and intensity-modulated radiotherapy for cervical cancer. Clin Oncol (R Coll Radiol). 2008;20:417-25.
5. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. Int J Gynaecol Obstet. 2009;105:107-8.
6. Nijman HW, Khalifa M, Covens A. What is the number of lymph nodes required for an" adequate" pelvic lymphadenectomy? Eur J Gynaecol Oncol. 2004;25:87-9.
7. Peters 3rd WA, Liu PY, Barrett 2nd RJ, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000;18:1606-13.
8. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs 3rd L, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340:1154-61.
9. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler Jr WC, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyureaas an adjunct to radiation therapy in stage IIB-IVA carcinomaof the cervix with negative para-aortic lymph nodes: agynecologic oncology group and southwest oncology groupstudy. J Clin Oncol. 1999;17:1339-48.
10. Small Jr W, Winter K, Levenback C, Iyer R, Gaffney D, Asbell S, et al. Extended-field irradiation and intracavitary brachytherapy combinedwithcisplatin chemotherapy for cervical cancer with positive para-aorticor high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys. 2007;68:1081-7.
11. Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1995;32:1289-300.
12. Li Z, Yang S, Liu L, Han S. A comparison of concurrent chemoradiotherapy and radiotherapy in Chinese patients with locally advanced cervical carcinoma: a multi-center study. Radiat Oncol. 2013;9:212.
13. Beriwal S, Gan GN, Heron DE, Selvaraj RN, Kim H, Lalonde R, et al. Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2007;68:166-71.
14. Jensen L, Hasselle MD, Rose BS, Nath SK, Hasan Y, Yashar CM, et al. Outcomes for cervical cancer patients treated with extended field intensity modulated radiation therapy and concurrent cisplatin. Int J Gynecol Cancer. 2011;81:S452-3.
15. 18FDG-PET\CT based simultaneous integrated boost for treatment of nodal positive cervical cancer. Radiat Oncol. 2014;9:83.
16. Mundt AJ, Roeske JC, Lujan AE, Yamada SD, Waggoner SE, Fleming G, et al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol. 2001;82:456-63.
17. Mundt AJ, Mell LK, Roeske JC. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys. 2003;56:1354-60.
18. Sakuragi N, Satoh C, Takeda N, Hareyama H, Takeda M, Yamamoto R, et al. Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. Cancer. 1999;85:1547-54.
19. Kamura T, Tsukamoto N, Tsuruchi N, Kaku T, Saito T, To N, et al. Histopathological prognostic factors in stage IIbcervical carcinoma treated with radical hysterectomy and pelvic-node dissection-an analysis with mathematical statistics. Int J Gynecol Cancer. 1993;3:219-25.
20. Koh WJ, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, et al. Cervical cancer. J Natl Compr Canc Netw. 2013;11:320-43.
21. Small Jr W, Mell LK, Anderson P, Creutzberg C, De Los Santos J, Gaffney D, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71:428-34.
22. Siu SS, Cheung TH, Lo KW, Yim SF, Chung TK. Is common iliac lymph node dissection necessary in early stage cervical carcinoma? Gynecol Oncol. 2006;103:58-61.
23. Michel G, Morice P, Castaigne D, Leblanc M, Rey A, Duvillard P. Lymphatic spread in stage Ib and II cervical carcinoma: anatomy and surgical implications. Obstet Gynecol. 1998;91:360-3.
24. Grigsby PW, Perez CA, Chao KS, Herzog T, Mutch DG, Rader J. Radiation therapy for carcinoma of the cervix with biopsy-proven positive para-aortic lymph nodes. Int J Radiat Oncol Biol Phys. 2001;49:733-8.
25. Varia MA, Bundy BN, Deppe G, Mannel R, Averette HE, Rose PG, et al. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a gynecologic oncology group study. Int J Radiat Oncol Biol Phys. 1998;42:1015-23.
26. Portelance L, Chao KS, Grigsby PW, Bennet H, Low D. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys. 2001;51:261-6.
27. Salama JK, Mundt AJ, Roeske J, Mehta N. Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2006;65:1170-6.
28. Gerszten K, Colonello K, Heron DE, Lalonde RJ, Fitian ID, Comerci JT, et al. Feasibility of concurrent cisplatin and extended field radiation therapy (EFRT) using intensity-modulated radiotherapy (IMRT) for carcinoma of the cervix. Gynecol Oncol. 2006;102:182-8.
29. Huang H, Liu J, Li Y, Wan T, Feng Y, Li Z, et al. Metastasis to deep obturator and para-aortic lymph nodes in 649 patients with cervical carcinoma. Eur J Surg Oncol. 2011;37:978-83.
30. Abu-Rustum NR, Barakat RR. Observations on the role of circumflex iliac node resection and the etiology of lower extremity lymphedema following pelvic lymphadenectomy for gynecologic malignancy. Gynecol Oncol. 2007;106:4-5.
31. Hoffman MS, Parsons M, Gunasekaran S, Cavanagh D. Distal external iliac lymph nodes in early cervical cancer. Obstet Gynecol. 1999;94:391-4.
32. Zhang X, Yu H. Evaluation of pelvic lymph node coverage of conventional radiotherapy fields based on bony landmarks in Chinese cervical cancer patients using CT simulation. J Zhejiang Univ Sci B. 2009;10:683-8.
33. McAlpine J, Schlaerth JB, Lim P, Chen D, Eisenkop SM, Spirtos NM. Radiation fields in gynecologic oncology: correlation of soft tissue (surgical) to radiologic landmarks. Gynecol Oncol. 2004;92:25-30.
34. Yin YJ, Li HQ, Sheng XG, Li XL, Wang X. Distribution pattern of circumflex iliac node distal to the external iliac node metastasis in stage IA to IIA cervical carcinoma. Int J Gynecol Cancer. 2014;24:935-40.
35. Buchsbaum HJ. Extrapelvic lymph node metastases in cervical carcinoma. Am J Obstet Gynecol. 1979;133:814-24.
36. Kasuya G, Toita T, Furutani K, Kodaira T, Ohno T, Kaneyasu Y, et al. Distribution patterns of metastatic pelvic lymph nodes assessed by CT/MRI in patients with uterine cervical cancer. Radiat Oncol. 2013;8:139.